Champions Oncology, Inc. (CSBR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Champions Oncology, Inc. in 2026. The next earnings report is expected on September 16, 2026.
Champions Oncology beat consensus estimates in its latest earnings report, with EPS of $0.01 versus an estimate of -$0.05 and revenue of $13.84 million, 7.4% above the $12.89 million expected. In the prior quarter both EPS and revenue missed expectations.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
